Arcutis Biotherapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Okay. Terrific. Let's get under right here. Welcome, everybody, to the second day of Goldman Sachs Healthcare Conference. My name is Chris Shibutani, and I'm with the research team, together with my colleague, Stephen Sloan, who does all the work on all the names. I'm very happy to have Arcutis here with us. Frank Watanabe, CEO; and in the audience, we have the rest of the team as well. So it's a great opportunity for everybody to interact at this incredible juncture here before the second quarter quite period as well. I was just trying to get an update.
But Frank, as I paid attention to the store for a couple of years now, there was kind of an outline of a goal and an objective to -- you would come up with a stand-alone entity that could address the needs of the dermatology community and really kind of break through in those had many difficult to do it beforehand. And you certainly did many things in terms of like developing a pipeline, taking it through clinical development and the commercialization. And with every
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
